Señales en vivo de ZGNX | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 dic 1970 @ 19:00):

Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States...

Stats
Volumen de hoy	11.25M
Volumen promedio	3.10M
Capitalización de mercado	0.00
EPS	$-0.980 ( 2022-02-28 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.56
ATR14	$0.603 (2.26%)

Insider Trading

Date	Person	Action	Amount	type
2022-03-07	Breitmeyer James B	Sell	1 250	Common Stock
2022-03-07	Breitmeyer James B	Sell	9 375	Stock Option (Right to Buy)
2022-03-07	Breitmeyer James B	Sell	6 250	Stock Option (Right to Buy)
2022-03-07	Breitmeyer James B	Sell	9 000	Stock Option (Right to Buy)
2022-03-07	Breitmeyer James B	Sell	10 000	Stock Option (Right to Buy)

INSIDER POWER
0.00
Last 100 transactions
Buy: 446 833 \| Sell: 2 096 567

Volumen Correlación

Largo: 0.49 (neutral)

Corto: 0.91 (very strong)

Signal:(77.726) Expect same movement, but be aware

Zogenix Inc Correlación

10 Correlaciones Más Positivas
KDNY	0.97
CEG	0.969
ATRS	0.969
ATCX	0.967
BWMX	0.961
XLRN	0.957
BSQR	0.957
CTSO	0.955
EYEN	0.952
PCTI	0.951

10 Correlaciones Más Negativas
TWKS	-0.966
SMSI	-0.955
LPSN	-0.954
PEAR	-0.951
VORB	-0.95
CNXC	-0.948
NAKD	-0.948
HILS	-0.939
RRGB	-0.936
BMBL	-0.935

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Zogenix Inc Correlación - Moneda/Commodity

0.13
( neutral )

0.68
( moderate )

0.09
( neutral )

-0.01
( neutral )

-0.59
( weak negative )

-0.82
( strong negative )

Zogenix Inc Finanzas

Annual	2021
Ingresos:	$81.69M
Beneficio Bruto:	$76.86M (94.08 %)
EPS:	$-4.24

FY	2021
Ingresos:	$81.69M
Beneficio Bruto:	$76.86M (94.08 %)
EPS:	$-4.24

FY	2020
Ingresos:	$13.64M
Beneficio Bruto:	$13.10M (96.03 %)
EPS:	$-3.90

FY	2019
Ingresos:	$3.65M
Beneficio Bruto:	$3.65M (100.00 %)
EPS:	$-9.74

Financial Reports:

No articles found.

Zogenix Inc

Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It is also developing MT1621, an investigational therapy for the treatment of a rare genetic disorder called thymidine kinase 2 deficiency. Zogenix, Inc. has a collaboration with Tevard Biosciences for the research, development and commercialization of novel gene therapies for Dravet Syndrome and other genetic epilepsies. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was incorporated in 2006 and is headquartered in Emeryville, California.